Center for Scientific Review: Notice of Closed Meeting, 75341 [2020-26030]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 228 / Wednesday, November 25, 2020 / Notices
A2058 (middle) and SK MEL 5
(lower) cell types
—Respondent reused and relabeled the
same source band to falsely
represent two different
experimental results in Figure 5 in
the 2005 AACR Presentation as
follows:
D Figure 5, lane 1 of the seventh row,
in the 2005 AACR Presentation,
representing pBad ser 75 expression
at 0 hour in control group
D Figure 5, lane 2 of the seventh row,
in the 2005 AACR Presentation,
representing pBad ser 75 expression
at 1 hour in control group
Dr. Panka entered into a Voluntary
Settlement Agreement and agreed to the
following:
(1) Respondent agreed to have his
research supervised for a period of three
(3) years beginning on November 9,
2020. Respondent agrees that prior to
the submission of an application for
PHS support for a research project on
which Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, Respondent shall
ensure that a plan for supervision of
Respondent’s duties is submitted to ORI
for approval. The supervision plan must
be designed to ensure the scientific
integrity of Respondent’s research
contribution. Respondent agrees that he
shall not participate in any PHSsupported research until such a
supervision plan is submitted to and
approved by ORI. Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of three (3) years
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals, setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of any PHS grant
applications (including supplements,
resubmissions, etc.), manuscripts
reporting PHS-funded research
submitted for publication, and abstracts.
The review will include a discussion
with Respondent of the primary data
represented in those documents and
VerDate Sep<11>2014
16:27 Nov 24, 2020
Jkt 253001
will include a certification to ORI that
the data presented in the proposed
application/publication are supported
by the research record.
(3) Respondent agreed that for a
period of three (3) years beginning on
November 9, 2020, any institution
employing him shall submit, in
conjunction with each application of
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract.
(4) If no supervisory plan is provided
to ORI, Respondent agreed to provide
certification to ORI at the conclusion of
the supervision period that he has not
engaged in, applied for, or had his name
included on any application, proposal,
or other request for PHS funds without
prior notification to ORI.
(5) Respondent agreed to exclude
himself voluntarily from serving in any
advisory capacity to PHS including, but
not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
a period of three (3) years, beginning on
November 9, 2020.
(6) As a condition of the Agreement,
Respondent will request that the
following papers and conference
abstract be corrected or retracted in
accordance with 42 CFR 93.407(a)(1)
and § 93.411(b):
• Mol Cancer 2011 Sep 19;10:115
• Mol Cancer 2013 Mar 5;12:17
• 2005 AACR Presentation
Respondent will copy ORI and the
Research Integrity Officer at HMS and
BIDMC on the correspondence.
75341
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Neuroscience, Biomarkers and
Therapeutics.
Date: December 7, 2020.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph G. Rudolph, Ph.D.,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7844, Bethesda, MD 20892, (301) 408–
9098, josephru@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 19, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–26030 Filed 11–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 20, 2020.
Elisabeth A. Handley,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
National Institutes of Health
[FR Doc. 2020–26100 Filed 11–24–20; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
General Medical Sciences Council.
The meeting will be open to the
public as indicated below, with a short
public comment period at the end. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review: Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
National Institute of General Medical
Sciences: Notice of Meeting
E:\FR\FM\25NON1.SGM
25NON1
]]>Agencies
[Federal Register Volume 85, Number 228 (Wednesday, November 25, 2020)]
[Notices]
[Page 75341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26030]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review: Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Neuroscience, Biomarkers and Therapeutics.
Date: December 7, 2020.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph G. Rudolph, Ph.D., Chief and Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186, MSC 7844, Bethesda, MD
20892, (301) 408-9098, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 19, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-26030 Filed 11-24-20; 8:45 am]
BILLING CODE 4140-01-P
